Wolfe Research initiated coverage on Beta Bionics with a new price target
$BBNX
Medical/Dental Instruments
Health Care
Wolfe Research initiated coverage of Beta Bionics with a rating of Outperform and set a new price target of $20.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2025 | $26.00 | Buy | Stifel |
| 10/1/2025 | $26.00 | Neutral → Buy | Goldman |
| 6/16/2025 | $26.00 | Buy | Truist |
| 6/12/2025 | $30.00 | Buy | Lake Street |
| 5/30/2025 | $16.00 | Neutral | Goldman |
| 5/30/2025 | $20.00 | Outperform | Wolfe Research |
| 2/24/2025 | Buy | BofA Securities | |
| 2/24/2025 | $30.00 | Buy | Lake Street |
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
Stifel resumed coverage of Beta Bionics with a rating of Buy and set a new price target of $26.00
Goldman upgraded Beta Bionics from Neutral to Buy and set a new price target of $26.00
Truist initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $26.00
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Third Quarter 2025 Financial Results & Key Metrics Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Durable Medical Equipment (DME) channel net sales of $21.0 million, up 45% compared to $14.5 million in the third quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $6.2 million, up 178% compared to $2.2 million in the thir
IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and
SCHEDULE 13G - Beta Bionics, Inc. (0001674632) (Subject)
10-Q - Beta Bionics, Inc. (0001674632) (Filer)
8-K - Beta Bionics, Inc. (0001674632) (Filer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
4 - Beta Bionics, Inc. (0001674632) (Issuer)
MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and
IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a
IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended September 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Third Quarter 2025 Financial Results & Key Metrics Net sales of $27.3 million, up 63% compared to $16.7 million in the third quarter of 2024. Durable Medical Equipment (DME) channel net sales of $21.0 million, up 45% compared to $14.5 million in the third quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $6.2 million, up 178% compared to $2.2 million in the thir
IRVINE, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its third quarter 2025 financial results after the financial markets close on Tuesday, October 28, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time). The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its full year guidance for the year ending December 31, 2025. Second Quarter 2025 Financial Results & Key Metrics Net sales of $23.2 million, up 54% compared to $15.0 million in the second quarter of 2024. Durable Medical Equipment (DME) channel net sales of $18.6 million, up 31% compared to $14.3 million in the second quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $4.6 million, up 498% compared to $0.8 million in the second